

# Improvement and clinical benefit analysis of low-dose esketamine on postoperative pain and sleep after sinus surgery

<b>Submission date</b> 21/11/2025	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 01/12/2025	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 27/11/2025	<b>Condition category</b> Ear, Nose and Throat	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Public, Scientific, Principal investigator

**Contact name**  
Dr Zi-ping Zhang

**Contact details**  
Guangzhou Twelfth People's Hospital  
Guangzhou  
China  
510000  
+86 20-38981288  
zhangzp202511@126.com

## Additional identifiers

## Study information

**Scientific Title**  
Effects of esketamine on postoperative pain and sleep

**Study objectives**  
To investigate the benefits of low-dose esketamine for pain relief and sleep quality improvement after sinus surgery and stable hemodynamics during perioperative period.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

approved 20/07/2021, The Human Research Ethics Committee of the Guangzhou Twelfth People's Hospital (Guangzhou Twelfth People's Hospital, Guangzhou, 510000, China; +86 20-38661509; srx8255@163.com), ref: 2021059

**Primary study design**

Interventional

**Allocation**

Randomized controlled trial

**Masking**

Blinded (masking used)

**Control**

Dose comparison

**Assignment**

Sequential

**Purpose**

Treatment

**Study type(s)****Health condition(s) or problem(s) studied**

Sinusitis and were scheduled to undergo functional endoscopic sinus surgery

**Interventions**

All patients were required to abstain from food for at least 6 hours and liquids for 2 hours before surgery. Intravenous access was established, and electrocardiogram (ECG), heart rate (HR), pulse oximetry, blood pressure (BP), and bispectral index (BIS) were monitored before induction of anesthesia.

The anesthesia protocol was as follows: prior to induction, patients received an intravenous injection of either physiological saline (control group), 0.2 mg/kg ketamine, or 0.3 mg/kg ketamine. Each solution was prepared in a syringe with a volume of 3.0 ml, and one was randomly assigned for use during induction using the online random number table method.

Anesthesia was then induced with intravenous injection of 0.1 mg/kg propofol medium/long-chain fat emulsion (1.0–2.0 mg/kg), 0.5 µg/kg sufentanil, and 0.2 mg/kg cisatracurium. After intubation under visual laryngoscopy, patients were connected to an anesthesia machine for mechanical ventilation. Ventilator parameters were adjusted according to patient condition, maintaining end-tidal carbon dioxide between 35 and 45 mmHg. Cisatracurium was administered intermittently during surgery. For anesthesia maintenance, patients received inhalation of 1.0–3.0 VOL% sevoflurane (0.65–1.70 times the minimum alveolar concentration [MAC]) and 2.0–6.0 mg/kg/h propofol, with BIS maintained between 40 and 60. Blood pressure was controlled to achieve a 20% reduction from baseline, using nitroglycerin or vasopressors if necessary. General

anesthesia drugs were discontinued near the end of surgery. All patients received anesthesia from the same team of anesthesiologists. Postoperative data were collected by an anesthesiologist specializing in data collection. The anesthesiologist, physician, and patients were blinded to group assignments during data collection.

## **Intervention Type**

Mixed

## **Primary outcome(s)**

1. Pain measured using visual analogue scale (VAS) at before and after treatment
2. Sleep measured using Pittsburgh Sleep Quality Index (PSQI) at before and after treatment
3. Depression measured using Hamilton Depression Rating Scale (HAM-D) at before and after treatment
4. Anxiety measured using Hamilton Anxiety Rating Scale (HAM-A) at before and after treatment
5. Psychological resilience measured using Connor-Davidson Resilience Scale (CD-RISC) at before and after treatment
6. Quality of life measured using Sino-Nasal Outcome Test 20 (SNOT-20) (Chinese version) at before and after treatment

## **Key secondary outcome(s)**

## **Completion date**

31/12/2023

# **Eligibility**

## **Key inclusion criteria**

1. Those who were 18 to 70 years old
2. Those without severe cardiovascular, respiratory, hepatic, or renal diseases
3. Those with a preoperative American Society of Anesthesiologists (ASA) classification of I to III
4. Those whose operation time was between 8 am and 6 pm
5. Those without a history of peptic ulcer disease
6. Those without a history of addiction to analgesic drugs
7. Those without a history of migraine disease
8. Those who could cooperate with physical examination and pain assessment

## **Healthy volunteers allowed**

No

## **Age group**

Mixed

## **Lower age limit**

18 years

## **Upper age limit**

70 years

**Sex**

All

**Total final enrolment**

135

**Key exclusion criteria**

1. Had an operative time of less than 1 hour or more than 3 hours
2. Had an operative bleeding volume of more than 200 ml
3. Patients with intracranial hypertension
4. Psychiatric patients such as schizophrenia, delusional disorders, and epilepsy
5. Patients with severe liver and renal conditions
6. Did not cooperate with postoperative treatment and follow-up visits
7. Allergies to the study medications or developed severe infections after surgery

**Date of first enrolment**

22/07/2021

**Date of final enrolment**

23/06/2022

## Locations

**Countries of recruitment**

China

## Sponsor information

**Organisation**

Twelfth Guangzhou City People's Hospital

**ROR**

<https://ror.org/03hm7k454>

## Funder(s)

**Funder type**

**Funder Name**

Guangzhou Municipal Science and Technology Project

**Alternative Name(s)**

Guangzhou Science and Technology Foundation, Guangzhou Science and Technology Plan, Sci-Tech Project Foundation of Guangzhou City, Science and Technology Program of Guangzhou City

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

China

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not expected to be made available